Targeting androgen receptor in macrophages inhibits phosphate-induced vascular smooth muscle cell calcification by decreasing IL-6 expression.


Journal

Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615

Informations de publication

Date de publication:
07 2020
Historique:
received: 09 01 2020
revised: 24 04 2020
accepted: 03 05 2020
pubmed: 11 5 2020
medline: 22 10 2020
entrez: 11 5 2020
Statut: ppublish

Résumé

Vascular calcification (VC) is a common complication of chronic kidney disease (CKD). However, its mechanisms remain unclear. VC, similar to atherosclerosis, is an inflammatory disease. Vascular smooth muscle cells (VSMCs) play a key role in VC progression. The androgen receptor (AR) in monocytes/macrophages plays an important role in inflammatory diseases. Here, we define the role of macrophage (MФ) AR in inorganic phosphate-induced VSMC calcification. Our results show that the conditioning medium (CM) of silencing AR in macrophages inhibits inorganic phosphate-induced human aortic smooth muscle cell (HASMC) calcification, and alleviates the transdifferentiation of HASMCs into osteoblasts for the protein expression of osteoblasts marker Runt-related transcription factor-2 (Runx2) in HASMCs decreased while that of smooth muscle cell marker SM22α increased. The effect of AR on HASMC calcification might mainly be mediated by the inflammatory cytokine IL-6. Silencing AR in monocytes/macrophages can dramatically decrease IL-6 expression. We also investigated how macrophage AR regulates IL-6. ChIP and luciferase assays indicate that AR directly binds to the ARE sequence in the promoter of the IL-6 gene to accelerate transcription and expression. To our knowledge, this is the first investigation that has established the correlation between AR and VC and identified the contribution of AR in the calcification of VSMCs. In addition, this study describes a novel target for therapeutic intervention in VC.

Identifiants

pubmed: 32387336
pii: S1537-1891(20)30004-5
doi: 10.1016/j.vph.2020.106681
pii:
doi:

Substances chimiques

ACTA2 protein, human 0
AR protein, human 0
Actins 0
Core Binding Factor Alpha 1 Subunit 0
IL6 protein, human 0
Interleukin-6 0
Phosphates 0
RUNX2 protein, human 0
Receptors, Androgen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106681

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declared that they have no conflicts of interest to this work.

Auteurs

Haiyan Pang (H)

The Kidney Diseases and Blood Purification Center, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China.

Longfei Xiao (L)

Department of Urology, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China.

Zhi Lu (Z)

The Kidney Diseases and Blood Purification Center, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China.

Haiyan Chen (H)

The Kidney Diseases and Blood Purification Center, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China.

Zhiqun Shang (Z)

Department of Urology, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China.

Ning Jiang (N)

Department of Urology, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China.

Xiaojuan Wang (X)

Department of Urology, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China.

Fang Wei (F)

The Kidney Diseases and Blood Purification Center, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China.

Aili Jiang (A)

The Kidney Diseases and Blood Purification Center, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China.

Yegang Chen (Y)

Department of Urology, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China. Electronic address: chenyegang2010@126.com.

Yuanjie Niu (Y)

Department of Urology, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin 300211, China. Electronic address: niuyuanjie@tmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH